SCHEMBL9258987

SCHEMBL9258987

C=CCOc1cc(C)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
L3MBTL1 Q9Y468 4/20 0.54
HPGD P15428 4/20 0.54
NPSR1 Q6W5P4 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
POLB P06746 2/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPK1 P28482 2/20 0.54
MEN1 O00255 1/20 0.54
USP2 O75604 1/20 0.54
ALOX12 P18054 1/20 0.54
KMT2A Q03164 1/20 0.54
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
HTR2A P28223 5/20 0.44
HTR2C P28335 5/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11409542 0.89 MAPT (0.50) MAPTL3MBTL1HPGDNPSR1CYP2C9
SCHEMBL22215851 0.83 KDM4E (0.46) MAPTL3MBTL1HPGDNPSR1CYP2C9
SCHEMBL16685038 0.81 GAA (0.57) HPGDCYP2C9CYP2C19ALDH1A1MEN1
SCHEMBL7816047 0.81 HPGD (0.51) MAPTHPGDCYP2C9POLBALDH1A1
SCHEMBL31536977 0.80 ALDH1A1 (0.45) MAPTHPGDALDH1A1MAPK1MEN1
SCHEMBL9781407 0.80 SYK (0.50) HPGDALDH1A1MAPK1ADRA2AADRA2B
SCHEMBL10157278 0.79 FLT3 (0.52) MAPTL3MBTL1HPGDNPSR1CYP2C9
SCHEMBL10399423 0.79 HTR2C (0.51) L3MBTL1ADRA2AADRA2BADRA2CHTR2A
SCHEMBL30826232 0.79 HTR2C (0.51) L3MBTL1ADRA2AADRA2BADRA2CHTR2A
SCHEMBL21175778 0.79 ADRA2A (0.43) HPGDALDH1A1MAPK1ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906539-B1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES HIVIH (FR) 2017-06-21 EP disclosed
EP-2906539-B1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES HIVIH (FR) 2017-06-21 EP disclosed
US-9604983-B2 Herbicidal 3-(2-benzyloxyphenyl)-2,4-dihydroxy-1,8-naphthyridine derivatives SYNGENTA LIMITED (GB) 2017-03-28 US disclosed
US-9475802-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-10-25 US disclosed
US-9475802-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-10-25 US disclosed
US-9475802-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-10-25 US disclosed
US-20160304509-A1 HERBICIDAL 3-(2-BENZYLOXYPHENYL)-2,4-DIHYDROXY-1,8-NAPHTHYRIDINE DERIVATIVES SYNGENTA LIMITED (GB) 2016-10-20 US disclosed
US-9260395-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-02-16 US disclosed
US-9260395-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-02-16 US disclosed
US-9260395-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-02-16 US disclosed
WO-2010130034-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 WO disclosed
WO-2009062285-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
WO-2009062289-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
WO-2009062308-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
WO-2009062288-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
US-5380654-A Process for the preparation of epoxides of means of microorganisms JAPAN ENERGY CORPORATION (JP) 1995-01-10 US disclosed
US-5376539-A Aerobic incubation of allyl phenyl ether with arthrobacter, brevibacterium, corynebacterium, pseudomonas or rhodococcus yields glycidyl phenyl ether NIPPON MINING CO., LTD. (JP) 1994-12-27 US disclosed
EP-0166527-B1 A PROCESS FOR THE PREPARATION OF EPOXIDES BY MEANS OF MICROORGANISMS NIPPON MINING COMPANY LIMITED (JP) 1991-04-03 EP disclosed
EP-0411787-A2 Microbiological production of 2,3-epoxypropyl ethers IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-02-06 EP disclosed
EP-0166527-A2 A process for the preparation of epoxides by means of microorganisms NIPPON MINING COMPANY LIMITED (JP) 1986-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304509-A1 HERBICIDAL 3-(2-BENZYLOXYPHENYL)-2,4-DIHYDROXY-1,8-NAPHTHYRIDINE DERIVATIVES CNPY2, CBR3, DRD1 MAPT 4781/4885L3MBTL1 693/4885HPGD 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.